News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Endologix Shares Are Hitting A Multiyear Low



5/19/2017 5:53:06 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Endologix Inc. (NASDAQ: ELGX) saw its shares hit a multiyear low following a meeting with the U.S. Food and Drug Administration (FDA). After this meeting, the company provided an update that its timeline for the Nellix Endovascular Aneurysm Sealing System (EVAS) may be longer than once thought.

Based on the FDA meeting and other internal analysis, the company has decided to seek U.S. approval of the Nellix EVAS by conducting a confirmatory clinical study with the previously updated Instructions for Use (IFU) and the Gen2 device design, which is currently sold in Europe and other international markets.

Read at 24/7 Wall St.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES